Mass General Department of Neurology
Edit

Mass General Department of Neurology

https://www.massgeneral.org/
Last activity: 23.09.2024
Active
Categories: CareCenterDiagnosticsEdTechHealthTechITMedTechNewsResearchVerification
Each year, Mass General admits more than 48,000 inpatients and handles nearly 1.5 million outpatient visits at its main campus and at its four health centers: in the Back Bay, Charlestown, Chelsea and Revere. Its Emergency Department records nearly 100,000 visits annually. Mass General is the only hospital in the United States to hold concurrent Level 1 verification for adult and pediatric trauma and burn care. The surgical staff performs more than 42,000 operations and the Department of Obstetrics and Gynecology delivers more than 3,600 babies each year.

Mass General conducts the largest hospital-based research program in the country, with an annual research budget of approximately $786 million. It is the oldest and largest teaching hospital of Harvard Medical School, where nearly all Mass General staff physicians serve on the faculty. Mass General is consistently ranked among the nation’s top hospitals by U.S. News and World Report.

In March 1994, the Mass General joined with Brigham and Women's Hospital to form Partners HealthCare System, Inc., an affiliation established to create an integrated health care delivery system providing excellent, cost-effective care while maintaining the hospital's historic dedication to teaching and research. In addition to the founding institutions, Mass General Brigham, formerly Partners HealthCare, now includes McLean Hospital, Spaulding Rehabilitation Hospital, North Shore Medical Center, Newton-Wellesley Hospital and Faulkner Hospital. Founded in 1811, Mass General is the third oldest general hospital in the United States and the oldest and largest in New England.

Learn more at https://www.massgeneral.org/about/
Likes
100.19K
Website visits
1.1M /mo.
Mentions
208
Location: United States, Massachusetts, Boston
Employees: 10001+
Phone: (617) 726-2000
Founded date: 1811

Mentions in press and media 208

DateTitleDescription
23.09.2024Bridging Hearts and Innovation: The Future of Medicine and Alternative ProteinsIn the heart of Beijing, a new chapter in medical innovation is unfolding. Professor Luo Min has been appointed as the Chairman of the Spine Neurocardiology Interdisciplinary Professional Committee. His mission? To revolutionize treatments ...
23.09.2024Professor Luo Min Appointed as Chairman of Spine Neurocardiology Interdisciplinary Professional Committee in China to Promote Development of Innovative Heart Disease TreatmentsBEIJING, Sept. 23, 2024 /PRNewswire/ -- Professor Luo Min, Doctor of Medicine (MD), from Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital, was recently appointed as the Chairman of the National Associ...
18.09.2024Safi Biotherapeutics: Manufactured Red Blood Cells Company Raises $5 Million (Seed)Safi Biotherapeutics—a company launched by former DARPA, Vertex, MIT, and MGH leaders—is leading the development of manufactured red blood cells (mRBCs) as an alternative to donor blood transfusions. The company recently announced a $5 mill...
18.09.2024TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy AgingHLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital ...
17.09.2024Pairwise: Cultivating the Future of Agriculture with Gene EditingIn the heart of Durham, North Carolina, a revolution is brewing. Pairwise, a technology company at the forefront of gene editing, has just secured $40 million in Series C funding. This latest round, led by Deerfield Management, pushes their...
17.09.2024Pairwise raises $40m series C, forms JV with Corteva to accelerate gene editing on row cropsPairwise, a startup pioneering gene editing in plants, has closed a $40m series C funding round and formed a five-year joint venture collaboration with agtech giant Corteva to advance the tech to increase climate resilience in corn and soy....
16.09.2024Pioneering New Frontiers in ALS and Cancer Treatment: The Role of QRL-101 and mIDH1 InhibitorsIn the realm of medical science, innovation is the lifeblood that fuels progress. Two recent developments stand out: QurAlis Corporation's QRL-101 for ALS and Vazyme's contributions to mIDH1 cancer treatment. Both represent significant stri...
16.09.2024Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer TreatmentNANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, whi...
15.09.2024New Hope in Overdose Treatment: Clear Scientific's Breakthrough Drug CS-1103In the relentless battle against the overdose crisis, a beacon of hope has emerged. Clear Scientific, a biopharmaceutical company based in Cambridge, Massachusetts, has unveiled promising results from its Phase 1 clinical trial of CS-1103. ...
12.09.2024The Brain Aneurysm Foundation Hosts Annual Research Grant Symposium as the Organization Marks 30 Years of Advocacy, Innovation and Education to Prevent Fatal RupturesHANOVER, Mass., Sept. 12, 2024 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, marked its 30th anniversary toda...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In